大行評級|招銀國際:下調新秀麗目標價至25.35港元 去年業績好壞參半
招銀國際發表報吿指出,新秀麗去年業績好壞參半,收入符合預期,但純利較該行預期低8%。儘管自去年第三季以來表現有所改善,但管理層預測今年首季的銷售將呈低至中單位數跌幅,亞洲區業務復甦,惟美國消費者信心仍可能疲弱。該行認為,由於旅行出遊正常化及高端零售市場復甦速度的不確定性,該行料新秀麗今年銷售及純利按年自然增長1.5%及1.8%。不過,持續的股票回購和雙重上市的進展可能會對股價帶來一些支持。該行將新秀麗的目標價由28港元下調至25.35港元,相當於今年預測市盈率13倍,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.